Why Talphera, Inc.’s (TLPH) Stock Is Down 14.29%
As of Thursday, August 13, Talphera, Inc.’s TLPH share price has dipped by 14.29%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Commentary & Analysis
Why Talphera, Inc.’s (TLPH) Stock Is Down 6.12%
As of Wednesday, August 12, Talphera, Inc.’s TLPH share price has dipped by 6.12%, which has investors questioning if this is right time to buy.Michael Rose
Why Talphera, Inc.’s (TLPH) Stock Is Up 5.56%
As of Thursday, August 06, Talphera, Inc.’s TLPH share price has surged by 5.56%, which has investors questioning if this is right time to sell.Michael Rose
Why Talphera, Inc.’s (TLPH) Stock Is Down 5.21%
As of Thursday, July 16, Talphera, Inc.’s TLPH share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Talphera, Inc.’s (TLPH) Stock Is Up 9.55%
As of Friday, July 10, Talphera, Inc.’s TLPH share price has surged by 9.55%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | TLPH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $62.3 | $674.5 | 17% |
|
| Shares Out (Mil) | 75.5 | 43.5 | 57% |
|
| Institutional Ownership | 91.9% | 84.6% | 60% |
|
| Float (Mil) | 25.2 | 47.3 | 33% |
|
| Beta | 0.70 | 0.71 | 41% |
|
| Avg Daily Volume (000s) | 125 | 290 | 40% |
|
| Price Change (52-week) |
132.7% | 69.3% | 95% |
|
| Growth | TLPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 18.8% | (1.4%) | 71% |
|
| EPS (5yr) | 48.7% | 15.0% | 92 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.0%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.050) | ($0.200) | ($0.245) | |
| Month Ago EPS | ($0.070) | ($0.255) | ($0.270) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.070) | ($0.255) | ($0.270) | |
| Year/Year Chg | (12.3%) | (41.0%) | (58.7%) | |
| Financials | TLPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($15) | ($11) | 26% |
|
| EPS (TTM) | ($0.237) | ($0.700) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($6) | 18% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $5 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $6 | 26% |
|
| Enterprise Value (Q1) (Mil) | $51 | $536 | 16% |
|
| Valuation | TLPH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.29 | 2.80 | 74% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TLPH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.1% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (69.6%) | (24.1%) | 9% |
|
| ROE | (143.4%) | (21.0%) | 6% |
|
| Liabilities to Assets | 46.3% | 32.3% | 38% |
|
| F-Score | 2 | 3 | 7% |
|
Talphera, Inc. did not pass any screens on 9/4/2026.
